Herein, we aim at building a combinatorial system comprising TZB, a HER2 targeting molecule, modified poly(DL-lactide-co-glycolide) (PLGA) and GNPs to combine targeted anticancer activity with photothermal potential for breast cancer therapy. This evidence concerns the gene ERBB2 and breast carcinoma.